The JV will focus on both Companies’ complementary nutraceuticals portfolios in categories such as metabolic, hospital nutrition, general wellness, women’s health and child nutrition for consumers across India.
- The JV will aim to extend the reach of Nestle‘s science-backed nutritional solutions to a broader customer base across the country by leveraging Dr. Reddy’s extensive retail and distribution network.
- Select brands will be licensed by both the JV partners to the JV company.
- JV is expected to be operational by Q2 of FY 2025.
Dr Reddy’s will hold a 51% stake in the JV, with Nestlé India holding the rest. Nestlé will have the option to increase its shareholding to up to 60% after six years, while Dr Reddy’s will retain a minimum of 40% shareholding even after Nestlé India exercises its call option.